EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Intradiscal treatment with recombinant human MMP-7 for patients with lumbar disc herniation: A sham-controlled multicenter, single-blind, dose-escalation, single-dose, phase I/IIa study

Hirotaka Haro, Tersuro Ohba, Kota Watanabe, Daisuke Nakashima, Satoshi Funayama, Hiroshi Yokomichi, Motohiro Kobayashi, Masaru Iwasaki, Hiromichi Komori, Masaya Nakamura

Journal of Orthopaedic Science · 2025-11 · 30 (6) · 981-991

DOI: 10.1016/j.jos.2025.02.002 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Orthopaedic Science, 2025-11. Verfasst von Hirotaka Haro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Integrated Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan. Electronic addre…. Hauptthemen laut MEDLINE: Intervertebral Disc Displacement, Lumbar Vertebrae. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This sham-controlled multicenter, single-blind, dose-escalation, single-dose, phase I/IIa study aimed to validate the safety and exploratory efficacy of intradiscal administration of recombinant human (rh) MMP-7 (KTP-001) for patients with lumbar disc herniation. METHODS: The cohort consisted of three groups. Cohort 1 (C1): three patients in the Sham group, three patients in the KTP-001 X-μg group. Cohort 2 (C2): six patients in the KTP-001 2X-μg group. Cohort 3 (C3): six patients in the KTP-001 4X-μg group. Under X-ray guidance, KTP-001 was injected into center part of the intervertebral disc at the level of herniated disc. The patients between the ages of 20 and 60 years had a subligamentous extrusion type of lumbar disc herniation at the L3-L4, L4-L5, or L5-S1 level. Adverse events, vital signs, clinical tests, magnetic resonance imaging (MRI), X-ray images, and anti-KTP-001 antibodies were used as primary endpoints to evaluate the safety of the investigational drug. The secondary endpoints were low back and leg pain intensity, neurological findings, Oswestry Disability Index, serum keratan sulfate pharmacodynamics, and hernia size on MRI to evaluate exploratory efficacy. The observation period was up to 24 weeks after administration. RESULTS: A total of 19 patients participated in the trial. No adverse events resulted in death or led to treatment discontinuation. Furthermore, CTCAE Grade 3 or higher adverse events did not occur. No changes were observed in the intervertebral discs or endplates that could be strongly attributed to drug administration based on MRI and X-ray radiographic. All the subjects remained negative for anti-KTP-001 antibody. Early after the treatment, we observed statistically significant improvements in neurological findings, SLR test results, and ODI results. CONCLUSIONS: Even if administered immediately after the onset of the disease and confirmation of the diagnosis, intradiscal treatment with KTP-001 may be safe and tolerable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intervertebral Disc DisplacementLumbar VertebraeHumansFemaleMaleMiddle AgedAdultSingle-Blind MethodTreatment OutcomeDose-Response Relationship, DrugYoung AdultRecombinant ProteinsMagnetic Resonance ImagingInjections, SpinalPain Measurement

Stichwörter der Autor:innen

Intradiscal treatmentLess invasive treatmentLumbar disc herniationMatrix metalloproteinaseRecombinant humanResorpton process

Substanzen

Recombinant Proteins

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Integrated Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan. Electronic address: haro@yamanashi.ac.jp.
  • Department of Orthopaedic Surgery, Integrated Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.
  • Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, 160-8582, Japan.
  • Department of Orthopaedic Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku, Tokyo, 160-8582, Japan; Department of Clinical Biomechanics, Keio University School of Medicine, 35 Shinanomachi, Shinjy…
  • Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu City, Shizuoka, 431-3192, Japan; Department of Radiology, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan.
  • Department of Health Sciences, University of Yamanashi, Shimokato, Chuo 409-3898, Yamanashi, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Haro, H., Ohba, T., Watanabe, K., Nakashima, D., Funayama, S., Yokomichi, H., Kobayashi, M., Iwasaki, M., Komori, H., & Nakamura, M. (2025). Intradiscal treatment with recombinant human MMP-7 for patients with lumbar disc herniation: A sham-controlled multicenter, single-blind, dose-escalation, single-dose, phase I/IIa study. Journal of Orthopaedic Science, 30(6), 981-991. https://doi.org/10.1016/j.jos.2025.02.002

Vancouver

Haro H, Ohba T, Watanabe K, Nakashima D, Funayama S, Yokomichi H, et al. Intradiscal treatment with recombinant human MMP-7 for patients with lumbar disc herniation: A sham-controlled multicenter, single-blind, dose-escalation, single-dose, phase I/IIa study. Journal of Orthopaedic Science. 2025;30(6):981-991. doi:10.1016/j.jos.2025.02.002

BibTeX
@article{Haro2025,
  author = {Haro, Hirotaka and Ohba, Tersuro and Watanabe, Kota and Nakashima, Daisuke and Funayama, Satoshi and Yokomichi, Hiroshi and Kobayashi, Motohiro and Iwasaki, Masaru and Komori, Hiromichi and Nakamura, Masaya},
  title = {Intradiscal treatment with recombinant human MMP-7 for patients with lumbar disc herniation: A sham-controlled multicenter, single-blind, dose-escalation, single-dose, phase I/IIa study},
  journal = {Journal of Orthopaedic Science},
  year = {2025},
  volume = {30},
  number = {6},
  pages = {981--991},
  doi = {10.1016/j.jos.2025.02.002}
}
Kostenlos starten →